登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Nature，4月27日，Antibody testing will enhance the power and accuracy of COVID-19-prevention trials》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-04-28

  • Antibody testing will enhance the power and accuracy of COVID-19-prevention trials

    Marc Lipsitch, Rebecca Kahn & Michael J. Mina

    Nature Medicine (2020)

    Researchers starting clinical trials of prevention measures for COVID-19 have a unique window of opportunity for collecting blood from the participants, at baseline and at the end of the trial, to be able to incorporate critical data into their analysis once serological tests for the causative coronavirus become available.

    Strategies for preventing infection with the coronavirus SARS-CoV-2 that causes COVID-19 are urgently needed. In the short term, these may include antiviral drugs and face masks1, while in the medium to longer term, this may include vaccines2.

  • 原文来源：https://www.nature.com/articles/s41591-020-0887-3
10浏览量
原文链接
相关报告

  • 《Nature，4月21日，The potential danger of suboptimal antibody responses in COVID-19》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-22
    • The potential danger of suboptimal antibody responses in COVID-19 Akiko Iwasaki & Yexin Yang Nature Reviews Immunology (2020) There is a desperate need for effective therapies and vaccines for SARS-CoV-2 to mitigate the growing economic crisis that has ensued from societal lockdown. Vaccines are being developed at an unprecedented speed and are already in clinical trials, without preclinical testing for safety and efficacy. Yet, safety evaluation of candidate vaccines must not be overlooked.
    125浏览量
    原文链接

  • 《Nature，4月29日，Antibody responses to SARS-CoV-2 in patients with COVID-19》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-30
    • Antibody responses to SARS-CoV-2 in patients with COVID-19 Quan-Xin Long, Bai-Zhong Liu, […]Ai-Long Huang Nature Medicine (2020) Abstract We report acute antibody responses to SARS-CoV-2 in 285 patients with COVID-19. Within 19 days after symptom onset, 100% of patients tested positive for antiviral immunoglobulin-G (IgG). Seroconversion for IgG and IgM occurred simultaneously or sequentially. Both IgG and IgM titers plateaued within 6 days after seroconversion. Serological testing may be helpful for the diagnosis of suspected patients with negative RT–PCR results and for the identification of asymptomatic infections.
    114浏览量
    原文链接